Multiple vaccine shots are needed to boost vasculitis patients’ immunity against COVID, especially if they have been treated ...

In a phase 2 trial, lusvertikimab significantly improves clinical and endoscopic outcomes in patients with moderate to severe ...

While still robust, CSL half-year results last Weds revealed impact of an “alarming” fall off in 'flu vax rates, especially ...

When CSL acquired Vifor, it raised eyebrows, given initial integration hurdles and generic competition for some Vifor ...

Australian investors are sending a clear message to listed companies this reporting season about their disapproval of mergers ...

On the heels of a late-stage clinical trial failure, Vifor Pharma has moved to bolster its pipeline by acquiring Spain's Sanifit and fellow Swiss biotech Inositec for a combined value of €225 ...

Australian biopharmaceutical company CSL said on Tuesday that falling immunisation rates in the U.S., its largest market, weighed on its vaccine sales and first-half profit growth, sending its shares ...

Vifor Pharma has forged a strategic partnership with Fresenius Kabi, focusing on marketing a portfolio of iron deficiency drugs. The partnership expands Vifor Pharma’s cooperation with Fresenius ...

Another ASX 200 blue chip share that could be a top buy for an SMSF is CSL. It is the biotechnology giant behind the CSL ...

Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today ...

Investors and analysts have lapped up the company’s pivot into data centres, one of the hottest subsectors in the world, and ...